Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2137568 | Leukemia Research | 2010 | 7 Pages |
Abstract
Azacitidine is currently the only drug to have shown a significant survival benefit over conventional care regimens in patients with International Prognostic Scoring System (IPSS) intermediate-2 (Int-2) and high-risk myelodysplastic syndromes (MDS), establishing it as an important new treatment for these individuals. However, several aspects of the practical use of azacitidine remain uncertain. This manuscript outlines recommendations discussed by a panel of experts, providing a practical guide for physicians to ensure optimal management of Int-2 and high-risk patients receiving azacitidine.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Pierre Fenaux, David Bowen, Norbert Gattermann, Eva Hellström-Lindberg, Wolf-Karsten Hofmann, Michael Pfeilstöcker, Guillermo Sanz, Valeria Santini,